Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
27(75%)
Results Posted
67%(4 trials)

Phase Distribution

Ph phase_1
14
39%
Ph phase_2
13
36%
Ph phase_3
8
22%

Phase Distribution

14

Early Stage

13

Mid Stage

8

Late Stage

Phase Distribution35 total trials
Phase 1Safety & dosage
14(40.0%)
Phase 2Efficacy & side effects
13(37.1%)
Phase 3Large-scale testing
8(22.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

27

trials recruiting

Total Trials

36

all time

Status Distribution
Active(29)
Completed(6)
Terminated(1)

Detailed Status

Active, not recruiting15
Recruiting12
Completed6
Not yet recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
36
Active
27
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 114 (40.0%)
Phase 213 (37.1%)
Phase 38 (22.9%)

Trials by Status

not_yet_recruiting26%
completed617%
recruiting1233%
withdrawn13%
active_not_recruiting1542%

Recent Activity

27 active trials
Showing 5 of 36
not_yet_recruitingphase_2

A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

NCT07700758
recruitingphase_3

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

NCT07405164
recruitingphase_3

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

NCT07489495
recruitingphase_2

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

NCT07187778
recruitingphase_2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075
View all 36 trials

Clinical Trials (36)

Showing 20 of 36 trialsScroll for more
NCT07700758Phase 2

A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

Not Yet Recruiting
NCT07405164Phase 3

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Recruiting
NCT07489495Phase 3

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

Recruiting
NCT07187778Phase 2

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

Recruiting
NCT04924075Phase 2

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Recruiting
NCT07227402Phase 3

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Recruiting
NCT07179770Phase 1

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

Recruiting
NCT04626518Phase 1

Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

Active Not Recruiting
NCT04626479Phase 1

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Active Not Recruiting
NCT05468697Phase 1

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Active Not Recruiting
NCT02974738Phase 1

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Active Not Recruiting
NCT07049926Phase 1

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Recruiting
NCT06428396Phase 2

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Active Not Recruiting
NCT07680205Phase 2

An Experimental Study of Belzutifan Impact on Catecholamine Metabolism

Recruiting
NCT07023432Phase 2

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

Recruiting
NCT04846920Phase 1

A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

Completed
NCT07593040Phase 2

Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma

Not Yet Recruiting
NCT05239728Phase 3

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Active Not Recruiting
NCT04195750Phase 3

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Active Not Recruiting
NCT04736706Phase 3

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
36